Diabetes: Impaired damage control

Diabetologia

Volumn 55, Issue 1, 2012, Pages 18-20

  Schaper, N C ^a,b   Havekes, B ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cytokines; Diabetic complications; DPP IV. Endothelium; Oral pharmacological agents; Pathogenetic mechanisms

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HIGH MOBILITY GROUP B1 PROTEIN; INCRETIN; PLACEBO; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR; VASCULOTROPIN;

CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC FOOT; GLYCEMIC CONTROL; HUMAN; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TISSUE INJURY; TISSUE REPAIR; WOUND HEALING IMPAIRMENT;

ANIMALS; DIPEPTIDYL PEPTIDASE 4; FEMALE; HMGB1 PROTEIN; HUMANS; MALE;

EID: 84856207737     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2368-1     Document Type: Review

References (21)

1. Andersson U, Tracey K (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 23:139-162
2. Yao D, Brownlee M (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59:249-255
3. Biscetti F, Straface G, De Cristofaro R et al (2010) High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 59:1496-1505
4. Straino S, Di Carlo A, Mangoni A et al (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 128:1545-1553 (Pubitemid 351693201)
5. Marchetti C, Di Carlo A, Facchiano F et al (2011) High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia. doi:10.1007/s00125-011-2213-6
6. Kirby M, Yu D, O'Connor S, Gorrell M (2010) Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 118:31-41
7. Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33:861-868
8. Bento C, Pereira P (2011) Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia 54:1946-1956
9. Porto A, Palumbo R, Pieroni M et al (2006) Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 20:2565-2566
10. Yan XX, Lu L, Peng WH et al (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:544-548
11. Kanellakis P, Agrotis A, Kyaw TS et al (2010) High-mobility group box protein 1 neutralization reduces development of dietinduced atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 31:313-319
12. Pachydaki SI, Tari SR, Lee SE et al (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807-815 (Pubitemid 43170881)
13. Huisamen B, Genis A, Marais E, Lochner A (2011) Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, prediabetic rats. Cardiovasc Drugs Ther 25:13-20
14. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298:H1454-H1465
15. Catrina S, Okamoto K, Pereira T, Brismar K, Poellinger L (2004) Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 53:3226-3232 (Pubitemid 39564499)
16. Gallagher KA, Liu ZJ, Xiao M et al (2007) Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1. J Clin Invest 117:1249-1259 (Pubitemid 46718413)
17. Fadini GP, Boscaro E, Albiero M et al (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes. Diabetes Care 33:1607-1609
18. Ceradini DJ, Yao D, Grogan RH et al (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283:10930-10938
19. Loot M, Kenter S, Au F, van Galen W, Middelkoop E, Bos J, Mekkes J (2002) Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol Mar 81:153-160 (Pubitemid 34308679)
20. Tchaikovski V, Olieslagers S, Bohmer FD, Waltenberger J (2009) Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 120:150-159
21. Thangarajah H, Yao D, Chang EI et al (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 106:13505-13510